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Fractional flow reserve is an important tool in the cardiac catheterization lab to assess the
physiological significance of coronary lesions. This article discusses the basic concepts
about FFR and its utility in clinical decision making.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
Coronary artery disease is a leading cause of death in devel-
oped countries and is increasingly being recognized in the
developing countries like India. Over the last 40 years the
decision to define the need for therapy and prognosis of cor-
onary artery disease is based on anatomical description of
extent of CAD as number of vessels affected by more than
50e70% stenosis.1 There is distinct shift in the guidelines for
revascularization now to physiologically significant lesions
rather than anatomically significant lesions based on data
from studies employing the Fractional Flow Reserve (FFR) for
clinical decision making.2e5 Therefore it is important to un-
derstand the basic concepts behind FFR and incorporate it into
as tool to make clinical decisions in patients with CAD.2. Normal coronary blood flow, Coronary
flow reserve (CFR), Relative CFR(r-CFR) and
Fractional flow reserve (FFR)
Under resting condition, the myocardium extracts the
maximum amount of oxygen delivered by the blood and in-
crease in myocardial oxygen demand is entirely met byra).
ociety of India. All rightschanges in coronary perfusion. Coronary and myocardial
blood flow is directly proportional to the coronary perfusion
pressure (Aortic diastolic pressureeLeft ventricular end dia-
stolic pressure) and inversely proportional to the resistance
offered by the coronary vessels at various levels. In normal
coronary arteries epicardial vessels or conductance vessels
(R1) offer negligible resistance to coronary perfusion and in-
crease in coronary blood flow in response to increased
myocardial oxygen demand (MVO2) is achieved by the dila-
tation of the resistance vessels at pre-capillary (R2) andmicro-
vascular levels (R3). The factors responsible for the changes in
vascular resistance and maintaining basal and maximal cor-
onary blood flow are local metabolites (adenosine during
ischemia), endothelial factors (NO) and neural tone.6
In normal heart conditions the ratio of maximum stress
flow to resting coronary blood flow in absolute units is called
coronary flow reserve (CFR) or absolute coronary flow
reserve.6 As defined by PET, in normal volunteers the resting
flow was 0.82 þ 0.06 cc/min/g, the maximum stress flow was
2.86 þ 1.29 cc/min/g and CFR was 3.55 þ 1.36.1 With develop-
ment of significant stenotic lesion in the epicardial artery the
micro-vascular resistance is decreased at basal conditions to
maintain resting flow thereby borrowing from the flow
reserve. Therefore in maximum stress conditions the hyper-
emic flow capacity is lowered and the ratio maximalreserved.
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significant epicardial stenosis, the diffuse arterial disease or
damage to microvasculature may limit the maximal vaso-
dilatory capacity and maximum achievable flow, thereby
reducing CFR. In some PET imaging studies the maximum
stress flow of<0.91 cc/min/g and absolute CFR of less than 1.74
were correlated with evidence of definite ischemia.7
In clinical practice Doppler flowwires and thermo-dilution
techniques are used to determine CFR. It is helpful in assess-
ing microvascular function but is highly dependent on he-
modynamic conditions (aortic pressure/heart rate).
In contrast, relative CFR is independent of hemodynamic
conditions. It describes the ratio of maximum hyperemic flow
in the diseased artery to maximum flow in the adjacent
normal arterial distribution.1 However, relative CFR is limited
in its utility clinically as atherosclerosis is a diffuse process
and affects multiple arterial segments. Therefore “normal”
arterial segment is not truly normal. Both absolute CFR and
relative CFR are flowderivedmeasures affected by the severity
of epicardial stenosis as well as the extent of disease in the
microvasculature. In order to overcome these limitations, Pijls
and De Bruyne developed the concept of Fractional Flow
Reserve (FFR) - a pressure derived relative coronary flow
reserve - to assess specifically epicardial coronary stenosis.8,9
In normal coronary arteries, the pressure in the distal
segment of the coronary artery is the same as aortic pressure
(origin of the artery). With development of progressive discrete
epicardial stenosis there will be a pressure drop across the
lesion in the resting or hyperemic state, depending on the
severity of the arterial narrowing. In a basal resting state, in
such a patient, the resting myocardial flow is maintained by
continuous alteration in microvascular resistance distal to the
stenosis. This constant auto-regulation creates a state ofwhere
the distal resistance and therefore the pressure gradient across
the lesion is variable and nonlinear in relation to the coronary
blood flow. By pharmacologically inducing maximal coronary
microvascular vasodilatation (i.e. hyperemia), coronary resis-
tance is lowered to a minimum steady state. In this condition,
theoretically, the relationship between the coronary perfusion
pressure and coronary blood flow is linear i.e. the maximum
myocardial blood flow distal stenosis is proportional to perfu-
sion pressure distal to discrete stenosis taking into account
both antegrade and collateral flow. Therefore one can use
pressuremeasurementsacross the lesionasa surrogateofflow.Table 1 e Vasodilators for testing Fractional Flow
Reserve.
Epicardial vasodilators:
Nitroglycerin: 200e400 mg IC, administer 30 s before 1st
measurement
Microvascular vasodilators:
Adenosine or ATP: 40 mg IC bolus in RCA,  80 mg IC bolus in LCA
Adenosine or ATP: 140 mg/kg/min IV (preferably through a central
venous line)
Regadeonson (Rapiscan): 400 mg single bolus IC or peripheral IV
Papaverine: 10e12 mg in the RCA, 15e20 mg in the LCA
IC: intracoronary, IV: Intravenously, RCA: Right Coronary Artery,
LCA: Left Coronary Artery, ATP: Adenosine triphosphate.In swine model with different levels of stenosis and aortic
pressures, Pijls et al showed that in a state of maximum hy-
peremia (minimal constant resistance) and low central venous
pressure (Pv), FFR (fraction ofmaximumnormal flow: a relative
CFR) is derived simply by ratio of mean pressure distal to the
stenosis (Pd) over the mean aortic pressure (Pa), a theoretical
pressure in the coronary artery in the absence of stenosis.8
FFR ¼ Qsmax=QNmax ¼ Pd Pv=Pa PvzPd=Pa
Qsmax: The maximal myocardial blood flow in a stenotic
territory.
QNmax: The theoretical maximal myocardial blood flow in
the same territory as Qsmax assuming the coronary artery
was completely normal (i.e. absence of any stenosis).
We now have a relatively simple method of assessing
the significance of discrete stenosis at any level in the arterial
segment. In normal coronary artery the mean aortic pressure
and distal coronary artery pressure will be the same. There-
fore, FFR (Pd/Pa) will be 1. The FFR of 0.7 and 0.5 implies that
the in the presence of stenosis the maximal achievable flow is
reduced to 70% and 50% of normal maximal flow. Therefore
lower the FFR value, more severe is the impairment in the
maximal achievable flow and more likely it to cause ischemia
below a threshold value. Similarly a change in FFR value
from 0.6 to 0.9 will indicate 50% improvement in the maximal
flow.3. Measurement of FFR in Cardiac
Catheterization Laboratory
Currently there are three systems available for measurement
of FFR in the catheterization laboratory: Radiwire system, St.
Jude Medical; Volcano Pressure wire system; and the Navvus
catheter-ACIST RXi System (Bracco, MN, USA).
In both the Radiwire system and Volcano system, the pres-
surewire is a small caliber 0.014-inch PTCAwire that contains a
pressure sensor at the junction of the distal radiopaque
shapeable tip to radiolucent body of the wire. Initially after
flushing the pressure wire loop with saline (placing the sensor
in the fluid), both the guide catheter transducer and the pres-
sure wire sensor are calibrated to zero. In the newer Radiwire
system, the wire calibration is done automatically. After
appropriate anticoagulation, the shaped pressure wire is
introduced using the introducer needle through the Y
connector and the sensor is advanced to the tip of the guide
catheter. The introducer needle is removed. The pressures
measured from the tip of the guide catheter (a fluid filled sys-
tem) and from the pressure sensor are equalized electronically
in the ascending aorta. After engagement of the coronary
arterial segment to be studied with the guiding catheter,
intracoronary nitroglycerin (200e400 mg) is administered. Sub-
sequently, the pressure wire is advanced carefully across the
coronary lesion, placing the sensor at least 3 cm distal to it.
Baseline Pd/Pa is recorded after disengaging the guide catheter
form the coronary ostium. Now a maximal hyperemic state is
induced by any of the currently recommended vasodilatory
agents (Table 1) and continuous recording of Pa, Pd and FFR is
done.10,11 When the mean Pa and Pd pressures reach a steady
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value for the arterial lesion studied. If one uses IVAdenosine or
Regadenoson, the pressure sensor can be pulled back slowly
along the length of the artery to the tip of the guide catheter to
determine the pressure drops along the entire length of the
artery. The pullback of pressure sensor into guide catheter also
checks for any significant electronic drift which may have
happened during the course of the recording, so that the value
of FFR can be properly interpreted. Pullback allows the assess-
ment of degree of pressure drops across serial multiple lesions.
Intracoronary bolus injections do not allow for the continuous
pullback.
In patients with multi-vessel disease, all arterial segments
in questions can be studied for physiologic significance simi-
larly and the mode of therapy can be determined based on
physiologic extent of CAD. In case of serial lesions in the ar-
tery, the lesion producing the maximum pressure drop is
treated first and FFR is repeated to determine the hemody-
namic significance of the residual disease. In presence of
diffuse arterial disease theremay not be specific pressure drop
but a gentle pressure change throughout the arterial segment
indicating no need for revascularization.4. FFR cut-off points for ischemic potential
The angiographic assessment of the degree of coronary ste-
nosis has a significant intra and inter observer variability,
especially in ostial, left main or bifurcation lesions. In addition
for the same degree of stenosis, the length of the lesion,
amount of viable myocardium supplied by the lesion, pres-
ence of diffuse disease distal to the lesion as well as collateral
flow to other arterial segment, may all determine the physi-
ologic significance of the lesion. Pijls et al correlated the FFR
values measured at a later date to presence or absence of
ischemia by multiple noninvasive modalities (nuclear imag-
ing studies, dobutamine stress echocardiograms, and exercise
stress testings) in the same group of patients.12 In the study,
FFR value of <0.75 determined the presence of reversible
ischemia with 93% accuracy (88% sensitivity, 100% specificity,
100% positive predictive value, 88% negative predictive value)
for a single discrete stenosis. FFR values between 0.75 and 0.8
conferred a gray zone and an FFR >0.8 correlatedwith absence
of ischemia on noninvasive testing.
This cut-off value of <0.75 (for treatment of patients with
single vessel disease) was tested initially in DEFER study and
subsequently validated in multiple studies including the ones
for left main disease.2,13e15 The DEFER study showed that it
was safe and preferable to avoid or defer stenting of the le-
sions with FFR>0.75. Such strategy was associated with lower
risk of death and MI (less than 1%per year) than routine
revascularization.
However in both FAME and FAME-2, patients with multi-
vessel disease were judged to have ischemic potential if the
FFR for the lesion was <0.8. The FAME study (using FFR > 0.8
defined as non-ischemic) showed that FFR-guided PCI strategy
verses angiographic guided PCI resulted in deferral of PCI in
almost 1/3 of the lesions and better 1 year clinical outcome
(combined endpoint of death, myocardial infarction, and
repeat revascularization at 1 year (FFR group 13.2% vs.Angiography group 18.3%, P ¼ 0.02).3e5 Based on the results of
these trials, the current coronary revascularization guidelines
for stable ischemic heart disease recommend strict dichoto-
mous cut-off value of less than 0.8 as appropriate for
revascularization.16e18
However, no single value of a test should be used for
clinical decision making as there is inherent variability in
repeated measurements besides other clinical factors; phy-
sician's clinical judgment should be taken into account for
therapeutic strategies. As suggested by Petraco et al, a single
FFR measurement of <0.75 or >0.85, can be used with con-
fidence clinically to revascularize the lesion or to defer
invasive therapy respectively.19 Single FFR value between
0.75 and 0.85 represents a gray zone requiring physician
judgment for deciding the course of management.5. Key points
- FFR is a single highly reliable and reproducible invasive
method to assess the ischemia producing potential of a
lesion with accuracy of more than 90%
- Currently a cutoff value of less than 0.8 is recommended
for revascularization
- Useful in assessment of intermediate coronary lesions in
stable ischemic heart disease (left main disease, bifurca-
tion disease, ostial disease, serial lesions, diffuse disease,
old MI, collateralized vessels)
- In ACS patients it can be used for non-culprit lesions and
after 7 days in the culprit lesions (not reliable in the culprit
vessels in acute stage)20
- While performing FFR important to equalize pressure
sensor at the tip of the guide catheter after removing the
introduced needle
- Pressure sensor should be placed atleast 3 cm distal to the
lesion
- Although a number of resting indices (resting Pd/Pa, IFR
etc) have been proposed, their diagnostic accuracy is
around 80%. However if resting Pd/Pa is < 0.8 on maximal
hyperemia, the FFRwill be< 0.8. If one is evaluating a single
focal stenosis one can use the baseline criteria for
revascularization
- Hyperemia is essential to achieve a steady state of mini-
mal microvascular resistance to correctly interpret lesion
physiology in all lesions (single or serial or diffuse
disease)
- For hyperemia IV adenosine or Regadenoson is better than
IC bolus for steady state and continuous pullback to assess
serial lesions
- Sometimes IV adenosine may not have adequate vaso-
dilatory effect due to rapid peripheral metabolism. In such
scenarios perform the response using incremental doses of
IC adenosine bolus
- For multi-vessel evaluation, IV adenosine is preferred over
Regadenoson because it has a longer lasting hemodynamic
effect
- Regadenoson has significantly larger blood pressure
lowering effect than IV adenosine (caution in patients with
borderline blood pressures)21
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use the lowest value in steady state
- Pullback slowly along the entire length of the artery
- Pullback to guide catheter to identify if there is any sig-
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